首次出版:最新修订:March 2009交付方式:特快专递(2-3天送达)
定购电话:0755-82571522、82571566、400-008-1522
24小时服务热线:138 0270 8576定制报告
版本 | 在线版 | 电子版或印刷版 | 电子版+印刷版 |
---|---|---|---|
优惠价 | RMB 6800 | RMB 7600 | RMB 7800 |
原价 | RMB 9600 | RMB 9600 | RMB 9800 |
订购报告,即可获得以下权益:
权益一:加1送1——加1000元、送1份在线版研究报告,多加多送,数量不限; 了解在线版报告详细清单,请点击咨询 >
权益二:加1送2——加1000元,送2个独家数据库,即上市公司投资项目库和企业拿地投资数据库;了解中投大数据 >
权益三:加1送200——加1000元,送超过200条在线版产业链图谱,使用期限为1年;查看产业链图谱清单 >
重磅推出产业研究大脑,是"产业研究的数字化高效工具",欢迎试用体验! |
||||
---|---|---|---|---|
产品名称 | 目标用户 | 核心功能定位 | 产品介绍 | 试用申请 |
产业研究大脑 | 政府、企业内关注产业发展的领导及工作人员 | 产业研究工作的一站式解决方案 | 详情 > | 申请 > |
联系电话:400 008 0586; 0755-82571568
微信扫码:
Chapter1
ExecutiveSummary
IndustrySnapshot1-1
ExecutiveSummary1-1
Chapter2
ExchangeRatesandGlossaryofTerms
GlossaryandExchangeRates2-1
GlossaryofTerms2-1
ExchangeRates2-4
Chapter3
IndustryChallenges
IndustryChallenges3-1
LackofCommonTechnologyStandardsinVirtualScreeningSolutions3-2
UncertaintyResultsinaSlowAdoptionofIn-silicoTechnologiesandModels3-2
TheReliabilityofModelsRequireRealExperimentalData3-3
IntegrationofDatafromVariousSources3-3
HighExpectationsDuetotheBenefitsofIn-silicoScreeningTools3-3
RegulatoryComplianceoftheDataCollectedandAnalysedbyIn-silicoTools3-4
Chapter4
MarketEngineeringResearchoftheVirtualScreeningMarketsinEurope
ForecastsfortheVirtualScreeningMarketsinEurope4-1
IntroductionandMarketOverview4-1
ResearchScopeandMethodology4-4
MarketSegmentation4-7
MarketEngineeringMeasurements4-7
MarketTrends4-8
MarketDrivers4-10
GreaterGenerationofDataIncreasestheDemandforBetterToolstoManageandAnalysetheData4-10
TheNeedtoIncreaseDrugProductivity4-11
In-silicoSolutionsIncreaseAdoptionandReturnonInvestment4-11
EliminationofFalseLeadsattheEarlyStageReducesAttritionRates4-11
VirtualScreeningDemandisDrivenbyanIncreaseinGovernmentalR&DSpending4-12
IncreasingTrendTowardsDryLaboratoryTechniques4-12
MarketRestraints4-12
LackofConsistentandAccurateDataCanRestraintheDevelopmenttoBuildBetterModels4-13
Non-standardandAlternativeDevelopingTechnologies
HindertheAcquisitionofHigh-quality,ReliableData4-13
AConservativeAttitudeonNewTechnologiesCanRestrainAdoption4-14
IncreasingUseofIn-houseIn-silicoTechnologiesMayMinimiseDrugPipelineTrials4-14
TotalRevenueForecasts4-14
TechnologyTrends4-17
SubstructureSearch4-17
SimilaritySearching4-17
QuantitativeStructureActivityRelationshipAnalysis4-18
Docking4-18
End-userTrends4-18
GeographicalTrends4-20
CompetitiveStructure4-23
FutureOpportunities4-25
Chapter5
MarketEngineeringResearchoftheVirtualScreeningMarketsinGermany
ForecastsfortheVirtualScreeningMarketsinGermany5-1
MarketEngineeringMeasurements5-1
TotalRevenueForecasts5-2
Chapter6
MarketEngineeringResearchoftheVirtual
ScreeningMarketsintheUnitedKingdom
ForecastsfortheVirtualScreeningMarketsintheUnitedKingdom6-1
MarketEngineeringMeasurements6-1
TotalRevenueForecasts6-2
Chapter7
MarketEngineeringResearchoftheVirtualScreeningMarketsinFrance
ForecastsfortheVirtualScreeningMarketsinFrance7-1
MarketEngineeringMeasurements7-1
TotalRevenueForecasts7-2
Chapter8
MarketEngineeringResearchoftheVirtualScreeningMarketsinSpain
ForecastsfortheVirtualScreeningMarketsinSpain8-1
MarketEngineeringMeasurements8-1
TotalRevenueForecasts8-2
Chapter9
MarketEngineeringResearchoftheVirtualScreeningMarketsinItaly
ForecastsfortheVirtualScreeningMarketsinItaly9-1
MarketEngineeringMeasurements9-1
TotalRevenueForecasts9-2
Chapter10
MarketEngineeringResearchoftheVirtual
ScreeningMarketsintheRest-of-Europe
ForecastsfortheVirtualScreeningMarketsintheRest-of-Europe10-1
MarketEngineeringMeasurements10-1
TotalRevenueForecasts10-2
Chapter11
MarketEngineeringStrategicRecommendations
StrategicRecommendations11-1
DevelopSolutionsthatEnableDataIntegrationfromaVarietyofTechniques11-2
HighQuality,AccurateandReliableData11-2
SegmentingtheMarketandClients11-3
SmallerBiotechCompaniesPresentNewOpportunities11-3
Chapter12
DecisionSupportDatabases
DecisionSupportDatabases12-1
Chapter13
DatabaseofKeyIndustryParticipants
KeyIndustryParticipants13-1
ListofKeyIndustryParticipants13-1
ListofFigures
Chapter2
ExchangeRatesandGlossaryofTerms
2-1VirtualScreeningMarket:
CurrencyExchangeRates(Europe),20062-4
Chapter3
IndustryChallenges
3-1VirtualScreeningMarket:
ImpactofTopIndustryChallenges(Europe),2007-20133-1
Chapter4
MarketEngineeringResearchoftheVirtualScreeningMarketsinEurope
4-1VirtualScreeningMarket:
MarketDriversRankedinOrderofImpact(Europe),2007-20134-10
4-2VirtualScreeningMarket:
MarketRestraintsRankedinOrderofImpact(Europe),2007-20134-13
4-3VirtualScreeningMarket:
RevenueForecasts(Europe),2003-20134-15
4-4VirtualScreeningMarket:
MarketSharebyGeographicalRegions(Europe),20064-21
4-5VirtualScreeningMarket:
MarketSharebyGeographicalRegions(Europe),20134-22
Chapter5
MarketEngineeringResearchoftheVirtualScreeningMarketsinGermany
5-1VirtualScreeningMarket:
RevenueForecasts(Germany),2003-20135-3
Chapter6
MarketEngineeringResearchoftheVirtualScreeningMarketsin
theUnitedKingdom
6-1VirtualScreeningMarket:
RevenueForecasts(UnitedKingdom),2003-20136-3
Chapter7
MarketEngineeringResearchoftheVirtualScreeningMarketsinFrance
7-1VirtualScreeningMarket:
RevenueForecasts(France),2003-20137-3
Chapter8
MarketEngineeringResearchoftheVirtualScreeningMarketsinSpain
8-1VirtualScreeningMarket:
RevenueForecasts(Spain),2003-20138-3
Chapter9
MarketEngineeringResearchoftheVirtualScreeningMarketsinItaly
9-1VirtualScreeningMarket:
RevenueForecasts(Italy),2003-20139-3
Chapter10
MarketEngineeringResearchoftheVirtualScreeningMarketsin
theRest-of-Europe
10-1VirtualScreeningMarket:
RevenueForecasts(Rest-of-Europe),2003-201310-3
Chapter12
DecisionSupportDatabases
12-1DecisionSupportDatabase:
VentureCapitalInvestmentinBiotechR&DinMillionUSD(WesternEurope),2002-201212-1
12-2DecisionSupportDatabase:
TotalHealthcareExpenditureinBillionUSD(WesternEurope),2002-201212-2
12-3DecisionSupportDatabase:
BiotechCompanies(WesternEurope),2002-201212-3
12-4DecisionSupportDatabase:
GovernmentR&DExpenditureinBiotechnologyinMillionUSD(WesternEurope),2002-201212-4
12-5DecisionSupportDatabase:
TotalPopulationinMillion(WesternEurope),2002-201212-5
ListofCharts
Chapter4
MarketEngineeringResearchoftheVirtualScreeningMarketsinEurope
4.1VirtualScreeningMarket:
DrugDiscoveryProcess(Europe),20064-2
4.2VirtualScreeningMarket:
OverviewofMarketStatus(Europe),20064-4
4.3VirtualScreeningMarket:
MarketEngineeringMeasurements(Europe),20064-8
4.4VirtualScreeningMarket:
RevenueForecasts(Europe),2003-20134-15
4.5VirtualScreeningMarket:
SegmentationbyEnd-users(Europe),20064-20
4.6VirtualScreeningMarket:
MarketSharebyGeographicalRegions(Europe),20064-21
4.7VirtualScreeningMarket:
MarketSharebyGeographicalRegions(Europe),20134-22
4.8VirtualScreeningMarket:
TopFiveMarketParticipants(Europe),20064-23
4.9VirtualScreeningMarket:
CommerciallyAvailableIn-silicoProducts(Europe),20064-25
Chapter5
MarketEngineeringResearchoftheVirtualScreeningMarketsinGermany
5.1VirtualScreeningMarket:
MarketEngineeringMeasurements(Germany),20065-2
5.2VirtualScreeningMarket:
RevenueForecasts(Germany),2003-20135-3
Chapter6
MarketEngineeringResearchoftheVirtualScreeningMarketsin
theUnitedKingdom
6.1VirtualScreeningMarket:
MarketEngineeringMeasurements(UnitedKingdom),20066-2
6.2VirtualScreeningMarket:
RevenueForecasts(UnitedKingdom),2003-20136-3
Chapter7
MarketEngineeringResearchoftheVirtualScreeningMarketsinFrance
7.1VirtualScreeningMarket:
MarketEngineeringMeasurements(France),20067-2
7.2VirtualScreeningMarket:
RevenueForecasts(France),2003-20137-3
Chapter8
MarketEngineeringResearchoftheVirtualScreeningMarketsinSpain
8.1VirtualScreeningMarket:
MarketEngineeringMeasurements(Spain),20068-2
8.2VirtualScreeningMarket:
RevenueForecasts(Spain),2003-20138-3
Chapter9
MarketEngineeringResearchoftheVirtualScreeningMarketsinItaly
9.1VirtualScreeningMarket:
MarketEngineeringMeasurements(Italy),20069-2
9.2VirtualScreeningMarket:
RevenueForecasts(Italy),2003-20139-3
Chapter10
MarketEngineeringResearchoftheVirtualScreeningMarketsin
theRest-of-Europe
10.1VirtualScreeningMarket:
MarketEngineeringMeasurements(Rest-of-Europe),200610-2
10.2VirtualScreeningMarket:
RevenueForecasts(Rest-of-Europe),2003-201310-3
The history of virtual screening dates back from efforts made in the 1970s where compound database searches using 2D structural fragments or 3D queries, and the subsequent automated docking of ligands into protein binding sites were introduced. In the mid 1980s, the use of computational chemistry was noted as the fastest method within drug discovery. With the increasing regulatory climate, techniques such as high throughput screening and combinatorial
chemistry were expected to quicken the process of discovering drugs. However, these processes resulted in creating further bottlenecks by 'spewing' hundreds of thousands of compounds at receptors, which proved to be very inefficient. Today, the aim of virtual screening is to identify leads, and thus the objective is to find molecules that bind to the target with good predicted potency.